Allied Market Research

2024

Etoricoxib Intermediate Market

Etoricoxib Intermediate Market Size, Share, Competitive Landscape and Trend Analysis Report by Type and by Indication : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) that explicitly targets enzymes responsible for inflammation and pain namely cyclooxygenase-2 and COX-2. Some of the NSAIDs can be used in a single dose to treat various types of pain; it can also be used for post-surgical pains.

The growth of the global Etoricoxib market is driven by increase in prevalence of various chronic and acute diseases and surge in geriatric population. Moreover, rise in demand for cost effective anti-inflammatory drugs is anticipated to boost the growth of this market. However, stringent guidelines set by regulating authorities for pharmaceutical products is expected to hinder the market growth.

The global Etoricoxib intermediate market is segmented on the basis of type of manufacturing, indication, and geography. Based on type of manufacturing, it is bifurcated into in-house manufacturing and contract manufacturing organizations. Based on indication, the market is divided into rheumatoid arthritis, psoriatic arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain, and others. By geography, it is analyzed across North America, Europe, Asia Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Bayer Corporation, Novacap Inc., Abbott Laboratories, Pfizer Inc, Geri-Care Pharmaceuticals, Perrigo Company, Kopran Ltd., Merck Sharp & Dohme Corp., Sun Pharmaceutical Industries Ltd, GlaxoSmithKline, are provided in this report.

Key Benefits

  • The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
  • Extensive analysis of the market is conducted by following key product positioning and monitoring the top competitors within the market framework
  • It offers a quantitative analysis¬†to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
  • Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

Etoricoxib Intermediate Market Report Highlights

Aspects Details
icon_5
By Type
  • In-House Manufacturing
  • Contract Manufacturing Organizations
icon_6
By Indication
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Osteoarthritis
  • Ankylosing Spondylitis
  • Chronic Low Back Pain
  • Acute Pain
  • Others
icon_7
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
icon_8
Key Market Players

Perrigo Company, Sun Pharmaceutical Industries Ltd., Novacap Inc., Abbott Laboratories, Bayer AG, GlaxoSmithKline, Pfizer Inc., Kopran Ltd., Geri-Care Pharmaceuticals, Merck Sharp & Dohme Corp.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Etoricoxib Intermediate Market

Global Opportunity Analysis and Industry Forecast, 2023-2032